Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07645846
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital, Sun Yat-Sen UniversityNot Yet RecruitingPhase 2
NCT07645846Not Yet Recruiting
Phase 2
Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaFirst Affiliated Hospital...
NCT07645924
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineKallyope Inc.Not Yet RecruitingPhase 3
NCT07645924Not Yet Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute T...Kallyope Inc.
NCT07644390
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal Surgery Using Longitudinal Indices of Routine Blood Tests: A Single-Center Retrospective Cohort StudySixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
NCT07644390Completed
—
Development of a Dynamic Prediction Model for Crohn's Disease-Related Intestinal...Sixth Affiliated Hospital...
NCT07645508
Comparison of Conventional, Patient-Specific, and Augmented Reality Navigation in Reverse Total Shoulder ArthroplastyKrankenhaus Barmherzige Schwestern LinzActive Not Recruiting
NCT07645508Active Not Recruiting
—
Comparison of Conventional, Patient-Specific, and Augmented Reality Navigation i...Krankenhaus Barmherzige S...
NCT07643792
Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture SurgeryPeking University First HospitalNot Yet RecruitingPhase 4
NCT07643792Not Yet Recruiting
Phase 4
Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture...Peking University First H...
NCT07644208
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative HepatectomyShanghai Zhongshan HospitalNot Yet RecruitingPhase 2
NCT07644208Not Yet Recruiting
Phase 2
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatoc...Shanghai Zhongshan Hospit...
NCT07644052
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderPleoPharma, Inc.RecruitingPhase 3
NCT07644052Recruiting
Phase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cann...PleoPharma, Inc.
NCT07646418
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International UniversityRecruitingNot Applicable
NCT07646418Recruiting
Not Applicable
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International Univ...
NCT07646587
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants With Moderate - Severe COPDWindward BioRecruitingPhase 2
NCT07646587Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants...Windward Bio
NCT07645365
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialysis UnitAntalya Health Sciences UniversityCompleted
NCT07645365Completed
—
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialy...Antalya Health Sciences U...
NCT07645196
Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With DysmenorrheaVrije Universiteit BrusselNot Yet RecruitingNot Applicable
NCT07645196Not Yet Recruiting
Not Applicable
Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With Dys...Vrije Universiteit Brusse...
NCT07645430
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.Benha UniversityCompletedNot Applicable
NCT07645430Completed
Not Applicable
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and...Benha University
NCT07644013
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First HospitalRecruiting
NCT07644013Recruiting
—
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First H...
NCT07643766
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisEnveda TherapeuticsNot Yet RecruitingPhase 2
NCT07643766Not Yet Recruiting
Phase 2
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in...Enveda Therapeutics
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07644091
Psychosocial Burden and Quality of Life in Caretakers of Hepatobiliary Cancer PatientsMethodist Health SystemRecruiting
NCT07644091Recruiting
—
Psychosocial Burden and Quality of Life in Caretakers of Hepatobiliary Cancer Pa...Methodist Health System
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646366
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee OsteoarthritisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646366Not Yet Recruiting
Not Applicable
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee O...Riphah International Univ...
NCT07645625
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerUniversity Medical Center GroningenRecruitingPhase 4
NCT07645625Recruiting
Phase 4
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerUniversity Medical Center...
Result Breakdown
Not yet recruiting8 (40%)
Recruiting8 (40%)
Completed3 (15%)
Active, not recruiting1 (5%)
Not Specified6 (30%)
Phase 25 (25%)
not_applicable5 (25%)
Phase 32 (10%)
Phase 42 (10%)